Literature DB >> 1356817

Surface distribution and internalization of erbB-2 proteins.

L V Lotti1, C Di Lazzaro, C Zompetta, L Frati, M R Torrisi.   

Abstract

We report the localization over the cell surface and the early steps of antibody-induced internalization of the product of the erbB-2 proto-oncogene, structurally related to the epidermal growth factor receptor (EGFR). We show that erbB-2/p 185 is mostly excluded from endocytic pits on the cell surface. Incubation at 37 degrees C with an anti-erbB-2/p185 monoclonal antibody induces the rapid entry of the protein into the cell. Similar internalization is shown by a chimeric molecule EGFR/erbB-2 in response to EGF. Both the timing and the pathway of internalization followed by the erbB-2/p185 appear totally similar to those described for the EGFR. At variance with the normal erbB-2/p185, two mutant activated erbB-2 proteins are frequently localized within endocytic pits of the cell surface, indicating that mutations in the transmembrane regions may determine constitutive internalization of the protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356817     DOI: 10.1016/0014-4827(92)90075-j

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain.

Authors:  L Fiorentino; C Pertica; M Fiorini; C Talora; M Crescenzi; L Castellani; S Alemà; P Benedetti; O Segatto
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

2.  Cellular localization of the activated EGFR determines its effect on cell growth in MDA-MB-468 cells.

Authors:  Dustin C Hyatt; Brian P Ceresa
Journal:  Exp Cell Res       Date:  2008-09-11       Impact factor: 3.905

3.  A genetic screen for anchorage-independent proliferation in mammalian cells identifies a membrane-bound neuregulin.

Authors:  Davide Danovi; Catherine A Cremona; Gisela Machado-da-Silva; Sreya Basu; Luke A Noon; Simona Parrinello; Alison C Lloyd
Journal:  PLoS One       Date:  2010-07-26       Impact factor: 3.240

4.  Preclinical characterisation of 111In-DTPA-trastuzumab.

Authors:  Marjolijn N Lub-de Hooge; Jos G W Kosterink; Patrick J Perik; Hugo Nijnuis; Ly Tran; Joost Bart; Albert J H Suurmeijer; Steven de Jong; Pieter L Jager; Elisabeth G E de Vries
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

5.  Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake.

Authors:  E Hurwitz; I Stancovski; M Sela; Y Yarden
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

6.  Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity.

Authors:  C Di Lazzaro; G Digiesi; R Tecce; L V Lotti; M R Torrisi; P G Natali
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

7.  Molecules internalized by clathrin-independent endocytosis are delivered to endosomes containing transferrin receptors.

Authors:  S H Hansen; K Sandvig; B van Deurs
Journal:  J Cell Biol       Date:  1993-10       Impact factor: 10.539

8.  Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas.

Authors:  H Naundorf; K Parczyk; W Zschiesche; S Reinecke; B Büttner; G J Saul; B Sinn; I Fichtner
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.